柴胡疏肝散联合美沙拉嗪治疗中度溃疡性结肠炎临床观察

万朝星; 肖乔枫; 叶祯; 代雪莉; 郑凯杰; 叶菁

doi:10.16025/j.1674-1307.2024.11.008

您当前的位置：

首页 >

文章列表页 >

柴胡疏肝散联合美沙拉嗪治疗中度溃疡性结肠炎临床观察

临床研究 | 更新时间：2024-12-23

- 柴胡疏肝散联合美沙拉嗪治疗中度溃疡性结肠炎临床观察
- Clinical efficacy of Chaihu Shugan Powder Combined with mesalazine in treatment of moderate ulcerative colitis
- 北京中医药 2024年43卷第11期页码：1262-1265
- 作者机构：
  
  1.江西中医药大学研究生院，南昌 330004
  2.江西中医药大学临床医学院，南昌 330004
  3.江西中医药大学;附属医院消化二科，南昌 330006
- 作者简介：
  
  万朝星，男，27岁，硕士研究生。研究方向：中医药治疗消化系统疾病。
  叶菁，E-mail：yejing@163.com
- 基金信息：
  
  江西省卫健委科技计划项目(2021B587);全国大学生创新训练计划项目(202210412156);江西省大学生创新训练计划项目(S202110412045X)
- DOI：10.16025/j.1674-1307.2024.11.008
  中图分类号：
- 纸质出版日期：2024-11-25，
  
  收稿日期：2023-11-26，
- 稿件说明：
移动端阅览
万朝星，肖乔枫，叶祯，等.柴胡疏肝散联合美沙拉嗪治疗中度溃疡性结肠炎临床观察［J］.北京中医药，2024，43（11）：1262-1265.

WAN Zhaoxing,XIAO Qiaofeng,YE Zhen,et al.Clinical efficacy of Chaihu Shugan Powder Combined with mesalazine in treatment of moderate ulcerative colitis[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(11):1262-1265.
万朝星，肖乔枫，叶祯，等.柴胡疏肝散联合美沙拉嗪治疗中度溃疡性结肠炎临床观察［J］.北京中医药，2024，43（11）：1262-1265. DOI： 10.16025/j.1674-1307.2024.11.008.

WAN Zhaoxing,XIAO Qiaofeng,YE Zhen,et al.Clinical efficacy of Chaihu Shugan Powder Combined with mesalazine in treatment of moderate ulcerative colitis[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(11):1262-1265. DOI： 10.16025/j.1674-1307.2024.11.008.

摘要

目的

观察柴胡疏肝散联合美沙拉嗪对中度溃疡性结肠炎（UC）患者焦虑抑郁状态、症状及生存质量的影响。

方法

选取2018年1月—2022年12月在江西中医药大学附属医院就诊的UC患者137例，根据治疗方案即是否服用柴胡疏肝散分为对照组82例、观察组55例进行回顾性研究。对照组给予美沙拉嗪口服，2 g/次，3次/d。观察组在对照组基础上联合中药柴胡疏肝散，1袋/次，2次/d。14 d为1个疗程，共2个疗程。对比2组治疗前后汉密尔顿焦虑量表（HAMA）评分、汉密尔顿抑郁量表（HAMD）评分、改良Mayo评分、炎症性肠病问卷调查（IBDQ）评分。

结果

治疗后，2组HAMA、HAMD评分均较治疗前降低（

0.05），且观察组低于对照组（

0.05）。2组Mayo、IBDQ评分均较治疗前改善（

0.05），且观察组优于对照组（

0.05）。

结论

柴胡疏肝散联合美沙拉嗪可显著改善中度UC患者焦虑抑郁状态、症状及生存质量，效果优于单用美沙拉嗪治疗。

Abstract

Objective

To observe the effect of Chaihu Shulang Powder combined with mesalazine on the anxiety-depression status， symptoms， and quality of life in patients with moderate ulcerative colitis （UC）.

Methods

A retrospective study was conducted on 137 UC patients who were treated at the Affiliated Hospital of Jiangxi University of Chinese Medicine from January 2018 to December 2022. According to the treatment plan， patients were divided into two groups： the control group （82 cases） and the observation group （55 cases）. The control group was treated with oral mesalazine （2 g per dose， 3 times per day）. The observation group received the same mesalazine treatment， with the addition of Chaihu Shulang Powder （1 packet per dose， 2 times per day）. One treatment course lasted 14 days， and the total treatment duration was 2 courses. The Hamilton Anxiety Scale （HAMA）， Hamilton Depression Scale （HAMD）， Modified Mayo Score， and Inflammatory Bowel Disease Questionnaire （IBDQ） scores were compared between the two groups before and after treatment.

Results

After treatment， both the HAMA and HAMD scores decreased in both groups（

0.05）， with the observation group showing significantly lower scores than the control group（

0.05）. The Mayo and IBDQ scores also improved in both groups（

0.05）， with the observation group showing better results than the control group（

0.05）.

Conclusion

Chaihu Shulang Powder combined with mesalazine can significantly improve the anxiety-depression status， symptoms， and quality of life in patients with moderate UC， and its effect is superior to mesalazine treatment alone.

关键词

溃疡性结肠炎柴胡疏肝散美沙拉嗪生存质量焦虑抑郁

Keywords

Ulcerative colitisChaihu Shugan Powdermesalazinequality of lifeanxietydepression

references

NG SC, SHI HY, HAMIDI N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017,390(10114):2769-2778.

OUYANG Q, TANDON R, GOH KL, et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region[J]. J Gastroenterol Hepatol, 2006,21(12):1772-1782.

匡琪,王爱祥,向瑶.心理因素、肠道菌群、环境与溃疡性结肠炎发病的关系分析[J].中国卫生统计,2021,38(5):742-745,749.

NAVABI S, GORREPATI VS, YADAV S, et al. Influences and impact of anxiety and depression in the setting of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2018,24(11):2303-2308.

GAO X, TANG Y, LEI N, et al. Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease[J]. Sci Rep, 2021,11(1):1440.

吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J].中国实用内科杂志,2018,38(9):796-813.

张景岳.景岳全书[M].太原：山西科学技术出版社,2006:782.

金玲,杨钦河,张玉佩,等.疏肝健脾方药对非酒精性脂肪性肝炎大鼠肝组织TNF-α、IL-6及IL-1的影响[J].暨南大学学报(自然科学与医学版),2012,33(2):161-166.

蒋华,武国营,蒋荣伟.柴胡疏肝散联合美沙拉秦肠溶片治疗溃疡性结肠炎的疗效及对炎症因子及血流动力学指标的影响[J].血栓与止血学,2020,26(5):745-747.

张明园，何燕玲.精神科评定量表手册[M].长沙:湖南科学技术出版社,2015：182-183.

沈洪,唐志鹏,唐旭东,等.消化系统常见病溃疡性结肠炎中医诊疗指南（基层医生版）[J].中华中医药杂志,2019,34(9):4155-4160.

欧阳钦.溃疡性结肠炎临床诊断指南[J].临床消化病杂志,2007,19(1):4-6.

FEUERSTEIN JD, ISAACS KL, SCHNEIDER Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis[J]. Gastroenterology, 2020,158(5):1450-1461.

HAMILTON M. The assessment of anxiety states by rating[J]. BrJ Med Psychol, 1959,32(1):50-55.

HAMILTON M. A rating scale for depression[J]. J Neurol Neurosurg Psychiatry,1960,23:56-62.

李军祥,陈誩.溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):105-111,120.

MANCINA RM， PAGNOTTA R， PAGLIUSO C， et al. Gastrointestinal symptoms of and psychosocial changes in inflammatory bowel disease: a nursing-led cross-sectional study of patients in clinical remission[J]. Medicina (Kaunas， Lithuania)， 2020，56(1):1-9.

GRACIE DJ， GUTHRIE EA， HAMLIN PJ， et al. Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease[J]. Gastroenterology， 2018，154(6):1635-1646,e3.

周瑾,黄菲,吴晓俊.柴胡疏肝散抗抑郁化学成分和药理作用研究进展[J].中药药理与临床,2019,35(2):174-179.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

白头翁汤治疗溃疡性结肠炎的信号通路机制分析

榆苋方保留灌肠对大肠湿热型溃疡性结肠炎大鼠PXR/NF-κB信号通路及炎症因子的调控作用研究

清热健脾调肠方对DSS结肠炎小鼠的作用及机制

黄连通过调控肠黏膜上皮细胞AQPs蛋白表达改善溃疡性结肠炎腹泻的机制研究

清热化湿祛瘀方对轻中度溃疡性结肠炎患者肠道菌群的影响